<p>2025 年 10 月 30 日- 上午 06:50</p>
<p>新泽西州伍德克利夫湖，2025 年 10 月 30 日（全球新闻通讯）——Eagle Pharmaceuticals, Inc.（OTCMKTS: EGRX）（“公司” 或 “Eagle”）今天宣布，其董事会（“董事会”）已通过对现有有限期限股东权利计划（经修订的 “权利计划”）的修订（“修订”），将权利计划的期限延长一年至 2026 年 10 月 30 日，立即生效。</p>
<p>对权利计划的修订是为了应对公司普通股交易价格的持续重大波动。该修订将增加收购方在权利计划触发时可能面临的潜在稀释。因此，修订后的权利计划旨在使所有公司的股东有机会实现其投资的长期价值，并减少任何个人或团体通过公开市场积累或其他方式在未适当补偿所有股东或未给予董事会足够时间做出明智判断和采取符合公司及其股东最佳利益的行动的情况下控制公司的可能性。</p>
<p>董事会并未因特定的收购威胁而通过对权利计划的延长。此外，权利计划并不妨碍董事会与各方接洽或接受收购提案，如果董事会认为这符合公司及所有股东的最佳利益。</p>
<p>修订后的权利计划将于 2026 年 10 月 30 日自动到期，除非公司提前赎回或交换权利。只有当某个人或团体（“收购方”）获得或发起收购要约以获取 Eagle 已发行普通股 10% 或以上的实益所有权（在权利计划中描述的被动机构投资者为 15%）时，权利才可行使。任何在 2024 年 10 月 30 日权利计划首次公告时，实益拥有 Eagle 已发行普通股超过适用阈值的股东将按其当前持股水平享有祖父条款，但不得在不触发权利计划的情况下增加其持股。一旦权利可行使，根据权利计划，每个权利将使其持有者（收购方除外，其权利将失效）有权以 20.00 美元的价格购买额外的 Eagle 普通股，购买的股票市值为该行使价格的两倍。此外，权利计划具有惯常的翻转和交换特征。除修订中另有规定外，权利计划的条款保持不变，继续有效。</p>
<p>Eagle 的股东目前无需就权利或权利计划采取任何进一步行动。</p>
<p><strong>关于 Eagle Pharmaceuticals, Inc.</strong></p>
<p>Eagle 是一家全面整合的制药公司，拥有研发、临床、制造和商业专业知识。Eagle 致力于开发创新药物，以显著改善患者的生活。Eagle 的商业化产品包括 PEMFEXY®、RYANODEX®、BENDEKA®、BELRAPZO®、TREAKISYM®（日本）以及通过其全资子公司 Acacia Pharma Inc.提供的 BYFAVO®和 BARHEMSYS®。Eagle 的肿瘤学和中枢神经系统/代谢重症护理管线包括有潜力解决多个疾病状态下未满足治疗需求的产品候选者，公司专注于开发有潜力成为癌症护理个性化医疗范式一部分的药物。更多信息请访问 Eagle 的网站 www.eagleus.com。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含关于未来事件或我们未来财务表现的 “前瞻性声明”。前瞻性声明是指那些不是历史事实的陈述。诸如 “预期”、“前进”、“将”、“会”、“可能”、“打算”、“保持”、“恢复”、“维持”、“潜在”、“准备”、“预计”、“相信”、“计划”、“寻求”、“继续”、“目标”、“估计” 等词语和短语旨在识别前瞻性声明。这些声明包括但不限于关于：权利计划的采用影响的声明，包括权利计划保护股东实现其投资长期价值的能力，以及有效地为董事会提供足够的时间以做出明智的判断并采取符合公司及其股东最佳利益的行动的能力，以及关于公司审查潜在融资和其他替代方案的过程的预期，包括公司可能决定追求的安排或交易的类型（如有）、该审查过程的范围和时间、任何此类安排或交易的潜在价值以及该审查过程的结果。所有这些声明都受到某些风险和不确定性的影响，其中许多是难以预测的，并且通常超出公司的控制，这可能导致实际结果与前瞻性信息和声明中表达、暗示或预测的结果有实质性差异。这些风险和不确定性包括但不限于：全球经济和政治状况；公司对第三方制造其产品的商业供应和临床供应的依赖；延迟或未能获得公司或其合作伙伴的产品候选者的监管批准，以及成功遵守适用于产品批准的联邦药品管理局、欧洲药品管理局和其他政府法规；监管环境的变化；监管批准过程的不确定性和时间；公司是否能够成功营销和商业化其产品；公司与其合作伙伴关系的成功；适用法律和法规的变化；与公司在 OTC 专家市场交易相关的公司普通股交易限制；对公司普通股价格和公司声誉的影响；公司改善财务报告内部控制的重大缺陷的补救能力；公司招聘、雇用和留住关键人员的能力；公司实现其旨在提高运营效率和重新调整销售和市场支出计划的预期收益的能力及其影响；公司对第三方制造其产品的商业供应和临床供应的依赖；地缘政治因素的影响，例如俄罗斯与乌克兰之间的冲突以及哈马斯、伊朗与以色列之间的冲突；延迟或未能获得公司或其合作伙伴的产品候选者的监管批准，以及成功遵守适用于产品批准的联邦药品管理局、欧洲药品管理局和其他政府法规；监管环境的变化；监管批准过程的不确定性和时间；公司是否能够成功营销和商业化其产品；公司与其合作伙伴关系的成功；诉讼和其他法律程序的结果以及额外诉讼和法律程序的风险；公司知识产权或第三方权利的强度和可执行性；来自其他制药和生物技术公司的竞争以及来自市场上仿制药进入者的竞争；在临床试验中观察到的意外安全性或有效性数据；临床试验现场激活或入组率低于预期；药物开发和进行临床试验中固有的风险；与公司关键会计政策相关的估计或判断中固有的风险，或公司任何估计或预测可能被证明不准确的风险；以及除上述因素外可能影响公司财务和业务预测的意外因素，这些因素可能导致公司的实际结果和结果与其估计和预测有实质性差异。读者被提醒不要对这些前瞻性声明过度依赖。本新闻稿中包含的所有前瞻性声明仅在作出之日有效。除法律要求的情况外，公司不承担更新此类声明以反映作出之日后发生的事件或存在的情况的义务。</p>
<p><strong>投资者关系联系人</strong></p>
<p>Lisa M. Wilson</p>
<p>电话：212-452-2793</p>
<p>电子邮件：lwilson@insitecony.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVMk5URTJOaU0zTWpNek9EYzFJekl3TVRZNE9EZz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVMk5URTJOaU0zTWpNek9EYzFJekl3TVRZNE9EZz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MmYwM2MzYWYtNjE2OC00YjRmLTk0NjAtZjRkZDA2ZTMzNjg2LTEwMjg0NjEtMjAyNS0xMC0zMC1lbg==/tiny/Eagle-Pharmaceuticals-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MmYwM2MzYWYtNjE2OC00YjRmLTk0NjAtZjRkZDA2ZTMzNjg2LTEwMjg0NjEtMjAyNS0xMC0zMC1lbg==/tiny/Eagle-Pharmaceuticals-Inc-.png"/></p>

Eagle制药

<p>Eagle Pharmaceuticals, Inc. 已将其有限期限股东权利计划延长一年至 2026 年 10 月 30 日，以应对其股价的重大波动。该修订旨在保护股东的长期投资价值，并防止任何个人或团体在没有适当补偿的情况下获得控制权。该计划允许股东在触发时以设定价格购买额外股份。董事会澄清，此次延长并非针对特定的收购威胁，也不妨碍与潜在收购提案的接洽</p>

<p>10/30/2025 - 06:50 AM</p>
<div class="lb-trans"><p>2025 年 10 月 30 日- 上午 06:50</p>
</div><p>WOODCLIFF LAKE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that its Board of Directors (the “Board”) has adopted an amendment (the “Amendment”) to its existing limited duration stockholder rights plan (as amended, the “Rights Plan”) to extend the duration of the Rights Plan by one year to October 30, 2026, effective immediately.</p>
<div class="lb-trans"><p>新泽西州伍德克利夫湖，2025 年 10 月 30 日（全球新闻通讯）——Eagle Pharmaceuticals, Inc.（OTCMKTS: EGRX）（“公司” 或 “Eagle”）今天宣布，其董事会（“董事会”）已通过对现有有限期限股东权利计划（经修订的 “权利计划”）的修订（“修订”），将权利计划的期限延长一年至 2026 年 10 月 30 日，立即生效。</p>
</div><p>The amendment to the Rights Plan was adopted in response to the ongoing significant dislocation in the trading price of the Company’s common stock. The amendment will have the effect of increasing the potential dilution an Acquiring Person would potentially face if the Rights Plan were triggered. Accordingly, the Rights Plan, as amended, is intended to enable all of the Company’s stockholders to have the opportunity to realize the long-term value of their investment and reduce the likelihood that any person or group gains control of the Company through open market accumulation or other means without appropriately compensating all stockholders or without providing the Board sufficient time to make informed judgments and take actions that are in the best interests of the Company and its stockholders.</p>
<div class="lb-trans"><p>对权利计划的修订是为了应对公司普通股交易价格的持续重大波动。该修订将增加收购方在权利计划触发时可能面临的潜在稀释。因此，修订后的权利计划旨在使所有公司的股东有机会实现其投资的长期价值，并减少任何个人或团体通过公开市场积累或其他方式在未适当补偿所有股东或未给予董事会足够时间做出明智判断和采取符合公司及其股东最佳利益的行动的情况下控制公司的可能性。</p>
</div><p>The Board did not adopt the extension to the Rights Plan in response to a specific takeover threat. In addition, the Rights Plan does not prevent the Board from engaging with parties or accepting an acquisition proposal, if the Board believes that it is in the best interests of the Company and all of its stockholders.</p>
<div class="lb-trans"><p>董事会并未因特定的收购威胁而通过对权利计划的延长。此外，权利计划并不妨碍董事会与各方接洽或接受收购提案，如果董事会认为这符合公司及所有股东的最佳利益。</p>
</div><p>The Rights Plan, as amended, will automatically expire on October 30, 2026, unless the rights are earlier redeemed or exchanged by the Company. The Rights will be exercisable only if a person or group (an “Acquiring Person”) acquires or launches a tender or exchange offer to acquire beneficial ownership (which includes certain synthetic equity interests) of 10% or more of Eagle’s outstanding common stock (15% in the case of a passive institutional investor as described in the Rights Plan). Any stockholders with beneficial ownership of Eagle’s outstanding common stock above the applicable threshold as of the time of the initial announcement of the Rights Plan on October 30, 2024 are grandfathered at their current ownership levels but are not permitted to increase their ownership without triggering the Rights Plan.Once the Rights become exercisable, pursuant to the Rights Plan, each Right will entitle its holder (other than any Acquiring Person, whose Rights will become void) to purchase, for $20.00, additional shares of Eagle’s common stock having a market value of twice such exercise price. In addition, the Rights Plan has customary flip-over and exchange features. Except as otherwise set forth in the Amendment, the terms of the Rights Plan are unchanged and remain in full force and effect.</p>
<div class="lb-trans"><p>修订后的权利计划将于 2026 年 10 月 30 日自动到期，除非公司提前赎回或交换权利。只有当某个人或团体（“收购方”）获得或发起收购要约以获取 Eagle 已发行普通股 10% 或以上的实益所有权（在权利计划中描述的被动机构投资者为 15%）时，权利才可行使。任何在 2024 年 10 月 30 日权利计划首次公告时，实益拥有 Eagle 已发行普通股超过适用阈值的股东将按其当前持股水平享有祖父条款，但不得在不触发权利计划的情况下增加其持股。一旦权利可行使，根据权利计划，每个权利将使其持有者（收购方除外，其权利将失效）有权以 20.00 美元的价格购买额外的 Eagle 普通股，购买的股票市值为该行使价格的两倍。此外，权利计划具有惯常的翻转和交换特征。除修订中另有规定外，权利计划的条款保持不变，继续有效。</p>
</div><p>Eagle’s stockholders do not need to take any further action with respect to the rights or the Rights Plan at this time.</p>
<div class="lb-trans"><p>Eagle 的股东目前无需就权利或权利计划采取任何进一步行动。</p>
</div><p><strong>About Eagle Pharmaceuticals, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Eagle Pharmaceuticals, Inc.</strong></p>
</div><p>Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), and BYFAVO® and BARHEMSYS® through its wholly owned subsidiary Acacia Pharma Inc. Eagle’s oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states, and the company is focused on developing medicines with the potential to become part of the personalized medicine paradigm in cancer care. Additional information is available on Eagle’s website at www.eagleus.com.</p>
<div class="lb-trans"><p>Eagle 是一家全面整合的制药公司，拥有研发、临床、制造和商业专业知识。Eagle 致力于开发创新药物，以显著改善患者的生活。Eagle 的商业化产品包括 PEMFEXY®、RYANODEX®、BENDEKA®、BELRAPZO®、TREAKISYM®（日本）以及通过其全资子公司 Acacia Pharma Inc.提供的 BYFAVO®和 BARHEMSYS®。Eagle 的肿瘤学和中枢神经系统/代谢重症护理管线包括有潜力解决多个疾病状态下未满足治疗需求的产品候选者，公司专注于开发有潜力成为癌症护理个性化医疗范式一部分的药物。更多信息请访问 Eagle 的网站 www.eagleus.com。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains “forward-looking statements” regarding future events or our future financial performance. Forward-looking statements are statements that are not historical facts. Words and phrases such as “anticipated,” “forward,” “will,” “would,” “could,” “may,” “intend,” “remain,” “regain,” “maintain,” “potential,” “prepare,” “expected,” “believe,” “plan,” “seek,” “continue,” “goal,” “estimate,” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements with respect to: the impacts of the adoption of the Rights Plan, including the ability of the Rights Plan to protect stockholders’ ability to realize the long-term value of their investment and to effectively provide the Board sufficient time to make informed judgments and take actions that are in the best interests of the Company and its stockholders, and expectations regardingthe Company’s process to review potential financing and other alternatives, including the types of arrangements or transactions, if any, that the Company may determine to pursue, the scope and timing of such review process, the potential value of any such arrangements or transactions and the outcome of such review process. All such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the Company’s control, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Such risks and uncertainties include, but are not limited to: global economic and political conditions; the Company’s reliance on third parties to manufacture commercial supplies of its products and clinical supplies of its product candidates; delay in or failure to obtain regulatory approval of the Company’s or its partners’ product candidates and successful compliance with Federal Drug Administration, European Medicines Agency and other governmental regulations applicable to product approvals; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; whether the Company can successfully market and commercialize its products; the success of the Company's relationships with its partners; changes in applicable laws and regulations; the limitations on trading of the Company’s common stock related to the Company’s trading on the OTC Expert Market; the impact on the price of the Company’s common stock and the Company’s reputation; the Company’s ability to remediate material weaknesses in its internal control over financial reporting; the Company’s ability to recruit, hire and retain key personnel; the ability of the Company to realize the anticipated benefits of its plan designed to improve operational efficiencies and realign its sales and marketing expenditures and the impacts thereof; the Company’s reliance on third parties to manufacture commercial supplies of its products and clinical supplies of its product candidates; the impacts of geopolitical factors such as the conflicts between Russia and Ukraine and Hamas, Iran and Israel; delay in or failure to obtain regulatory approval of the Company’s or its partners’ product candidates and successful compliance with Federal Drug Administration, European Medicines Agency and other governmental regulations applicable to product approvals; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; whether the Company can successfully market and commercialize its products; the success of the Company's relationships with its partners; the outcome of litigation and other legal proceedings and the risk of additional litigation and legal proceedings; the strength and enforceability of the Company’s intellectual property rights or the rights of third parties; competition from other pharmaceutical and biotechnology companies and competition from generic entrants into the market; unexpected safety or efficacy data observed during clinical trials; clinical trial site activation or enrollment rates that are lower than expected; the risks inherent in drug development and in conducting clinical trials; risks inherent in estimates or judgments relating to the Company’s critical accounting policies, or any of the Company’s estimates or projections, which may prove to be inaccurate; and unanticipated factors in addition to the foregoing that may impact the Company’s financial and business projections and may cause the Company’s actual results and outcomes to materially differ from its estimates and projections. Readers are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.</p>
<div class="lb-trans"><p>本新闻稿包含关于未来事件或我们未来财务表现的 “前瞻性声明”。前瞻性声明是指那些不是历史事实的陈述。诸如 “预期”、“前进”、“将”、“会”、“可能”、“打算”、“保持”、“恢复”、“维持”、“潜在”、“准备”、“预计”、“相信”、“计划”、“寻求”、“继续”、“目标”、“估计” 等词语和短语旨在识别前瞻性声明。这些声明包括但不限于关于：权利计划的采用影响的声明，包括权利计划保护股东实现其投资长期价值的能力，以及有效地为董事会提供足够的时间以做出明智的判断并采取符合公司及其股东最佳利益的行动的能力，以及关于公司审查潜在融资和其他替代方案的过程的预期，包括公司可能决定追求的安排或交易的类型（如有）、该审查过程的范围和时间、任何此类安排或交易的潜在价值以及该审查过程的结果。所有这些声明都受到某些风险和不确定性的影响，其中许多是难以预测的，并且通常超出公司的控制，这可能导致实际结果与前瞻性信息和声明中表达、暗示或预测的结果有实质性差异。这些风险和不确定性包括但不限于：全球经济和政治状况；公司对第三方制造其产品的商业供应和临床供应的依赖；延迟或未能获得公司或其合作伙伴的产品候选者的监管批准，以及成功遵守适用于产品批准的联邦药品管理局、欧洲药品管理局和其他政府法规；监管环境的变化；监管批准过程的不确定性和时间；公司是否能够成功营销和商业化其产品；公司与其合作伙伴关系的成功；适用法律和法规的变化；与公司在 OTC 专家市场交易相关的公司普通股交易限制；对公司普通股价格和公司声誉的影响；公司改善财务报告内部控制的重大缺陷的补救能力；公司招聘、雇用和留住关键人员的能力；公司实现其旨在提高运营效率和重新调整销售和市场支出计划的预期收益的能力及其影响；公司对第三方制造其产品的商业供应和临床供应的依赖；地缘政治因素的影响，例如俄罗斯与乌克兰之间的冲突以及哈马斯、伊朗与以色列之间的冲突；延迟或未能获得公司或其合作伙伴的产品候选者的监管批准，以及成功遵守适用于产品批准的联邦药品管理局、欧洲药品管理局和其他政府法规；监管环境的变化；监管批准过程的不确定性和时间；公司是否能够成功营销和商业化其产品；公司与其合作伙伴关系的成功；诉讼和其他法律程序的结果以及额外诉讼和法律程序的风险；公司知识产权或第三方权利的强度和可执行性；来自其他制药和生物技术公司的竞争以及来自市场上仿制药进入者的竞争；在临床试验中观察到的意外安全性或有效性数据；临床试验现场激活或入组率低于预期；药物开发和进行临床试验中固有的风险；与公司关键会计政策相关的估计或判断中固有的风险，或公司任何估计或预测可能被证明不准确的风险；以及除上述因素外可能影响公司财务和业务预测的意外因素，这些因素可能导致公司的实际结果和结果与其估计和预测有实质性差异。读者被提醒不要对这些前瞻性声明过度依赖。本新闻稿中包含的所有前瞻性声明仅在作出之日有效。除法律要求的情况外，公司不承担更新此类声明以反映作出之日后发生的事件或存在的情况的义务。</p>
</div><p><strong>Investor Relations Contact</strong></p>
<div class="lb-trans"><p><strong>投资者关系联系人</strong></p>
</div><p>Lisa M. Wilson</p>
<div class="lb-trans"><p>Lisa M. Wilson</p>
</div><p>T: 212-452-2793</p>
<div class="lb-trans"><p>电话：212-452-2793</p>
</div><p>E: lwilson@insitecony.com</p>
<div class="lb-trans"><p>电子邮件：lwilson@insitecony.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVMk5URTJOaU0zTWpNek9EYzFJekl3TVRZNE9EZz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTU2NTE2NiM3MjMzODc1IzIwMTY4ODg="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MmYwM2MzYWYtNjE2OC00YjRmLTk0NjAtZjRkZDA2ZTMzNjg2LTEwMjg0NjEtMjAyNS0xMC0zMC1lbg==/tiny/Eagle-Pharmaceuticals-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/MmYwM2MzYWYtNjE2OC00YjRmLTk0NjAtZjRkZDA2ZTMzNjg2LTEwMjg0NjEtMjAyNS0xMC0zMC1lbg==/tiny/Eagle-Pharmaceuticals-Inc-.png"/></p>

Eagle 制药董事会延长了有限期限的股东权利计划 | EGRX 股票新闻